(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/216584 A1

(51) International Patent Classification:
A61K 39/215 (2006.01) *C07K 16/10* (2006.01)
A61K 39/42 (2006.01) *C12N 15/11* (2006.01)
A61P 31/14 (2006.01) *C12N 15/50* (2006.01)

(21) International Application Number:
PCT/US2021/028207

(22) International Filing Date:
20 April 2021 (20.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/013,726 22 April 2020 (22.04.2020) US
63/072,354 31 August 2020 (31.08.2020) US

(71) Applicant: **AIRWAY THERAPEUTICS, INC.** [US/US]; 11804 Conrey Road, Suite #175, Cincinnati, Ohio 45249 (US).

(72) Inventors: **KINGMA, Paul**; c/o Airway Therapeutics, Inc., 11804 Conrey Road, Suite #175, Cincinnati, Ohio 45249 (US). **GRANT, Shawn**; c/o Airway Therapeutics, Inc., 11804 Conrey Road, Suite #175, Cincinnati, Ohio 45249 (US). **ARROYO-RODRÍGUEZ, Raquel**; c/o Airway Therapeutics, Inc., 11804 Conrey Road, Suite #175, Cincinnati, Ohio 45249 (US). **SALZBERG, Marc**; c/o Airway Therapeutics, Inc., 11804 Conrey Road, Suite #175, Cincinnati, Ohio 45249 (US).

(74) Agent: **FULLER, Michael, L.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** USE OF SURFACTANT PROTEIN D TO TREAT VIRAL INFECTIONS



FIG. 4C

(57) **Abstract:** Some embodiments of the methods and compositions provided herein relate to the use of surfactant protein D (SP-D) to treat or ameliorate a viral infection in a subject. In some embodiments, the viral infection comprises a coronavirus, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some embodiments include the use of certain formulations comprising a recombinant human SP-D (rhSP-D).

WO 2021/216584 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*